MedTrace Logo

A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma

NCT07791758 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 369

Last updated 2026-08-31

No results posted yet for this study

Summary

This study is an open-label, multi-center Phase Ib/II clinical trial evaluating the safety and efficacy of LBL-024 in combination with other drugs for the treatment of metastatic colorectal carcinoma (mCRC), aiming to evaluate the safety and efficacy of LBL-024 in combination with other drugs in the treatment of mCRC patients.

Conditions

  • Metastatic Colorectal Carcinoma

Interventions

DRUG

LBL-024 for Injection

intravenous infusion.

DRUG

Bevacizumab injection

intravenous infusion.

DRUG

Oxaliplatin injection

intravenous infusion.

DRUG

Capecitabine tablets

Oral.

DRUG

Fruquintinib Capsules

Oral.

Sponsors & Collaborators

  • Sun Yat-Sen University Cancer Center

    collaborator OTHER

  • Nanjing Leads Biolabs Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Ruihua Xu · Sun Yat-Sen University Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-04
Primary Completion
2030-09-04
Completion
2030-09-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07791758 on ClinicalTrials.gov